Clinical practice guidelines for the diagnosis and management of patients with acquired hemophilia A approved by The Japanese Society on Thrombosis and Hemostasis

[1]  M. Franchini,et al.  Acquired hemophilia A. , 2011, Advances in clinical chemistry.

[2]  C. Kessler,et al.  Consensus recommendations for the diagnosis and treatment of acquired hemophilia A , 2010, BMC Research Notes.

[3]  F. Baudo,et al.  Diagnosis and treatment of acquired haemophilia , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  P. Collins,et al.  Advances in the understanding of acquired haemophilia A: implications for clinical practice , 2010, British journal of haematology.

[5]  C. Kessler,et al.  International recommendations on the diagnosis and treatment of patients with acquired hemophilia A , 2009, Haematologica.

[6]  G. Lippi,et al.  Acquired factor VIII inhibitors. , 2008, Blood.

[7]  J. Takamatsu,et al.  A 3-year consecutive survey on current status of acquired inhibitors against coagulation factors in Japan , 2008 .

[8]  Y. Yatomi,et al.  Features of factor VIII activity measurement in Arg531His mutant detected in patients with mild hemophilia A , 2008 .

[9]  M. Taki,et al.  Methodological characteristics of Factor VIII : C inhibitor assays and the availability of inactivation treatment , 2008 .

[10]  S. Seremetis,et al.  Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  M. Franchini.  Rituximab in the treatment of adult acquired hemophilia A: a systematic review. , 2007, Critical reviews in oncology/hematology.

[12]  P. Collins.  Treatment of acquired hemophilia A , 2007, Journal of thrombosis and haemostasis : JTH.

[13]  L. Valentino,et al.  Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  T. Baglin,et al.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. , 2007, Blood.

[15]  J. Astermark,et al.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. , 2007, Blood.

[16]  W. Sperr,et al.  Rituximab for the treatment of acquired antibodies to factor VIII. , 2007, Haematologica.

[17]  M. Franchini.  Postpartum acquired factor VIII inhibitors , 2006, American journal of hematology.

[18]  聡 白幡,et al.  インヒビター保有血友病患者における遺伝子組換え活性型血液凝固 第VII因子製剤(注射用ノボセブン®)の長期的安全性および有効性 : 5年間の市販後調査中間解析報告 , 2006 .

[19]  R. Liesner,et al.  The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation , 2006, British journal of haematology.

[20]  M. Franchini,et al.  Acquired coagulation inhibitor-associated bleeding disorders: An update , 2005, Hematology.

[21]  P. Mannucci,et al.  Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  G. Tjønnfjord,et al.  Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  G. Mariani,et al.  Acquired hemophilia A: A concise review , 2005, American journal of hematology.

[24]  A. Shirahata,et al.  Successful steroid pulse treatment in childhood acquired haemophilia with nephrotic syndrome , 2005, Haemophilia.

[25]  D. Girelli,et al.  Clinical heterogeneity of acquired hemophilia A: a description of 4 cases. , 2005, Haematologica.

[26]  M. Shima,et al.  Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life‐threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  S. Amadori,et al.  Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. , 2004, Blood.

[28]  G. Kenet,et al.  Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors , 2004, Journal of thrombosis and haemostasis : JTH.

[29]  G. Tjønnfjord,et al.  Activated prothrombin complex concentrate (FEIBA®) treatment during surgery in patients with inhibitors to FVIII/IX , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  S. Sallah.  Treatment of acquired haemophilia with factor eight inhibitor bypassing activity , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[31]  P. Collins,et al.  A population based, unselected, consecutive cohort of patients with acquired haemophilia A , 2004, British journal of haematology.

[32]  G. Gaidano,et al.  Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. , 2004, Haematologica.

[33]  A. Mäkipernaa,et al.  Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  J. Delgado,et al.  Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors , 2003, British journal of haematology.

[35]  F. Decataldo,et al.  Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. , 2003 .

[36]  H. Ehrlich,et al.  Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[37]  M. Ragni,et al.  Acquired anti‐FVIII inhibitors in children , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[38]  J. Wan,et al.  Inhibitors against Factor VIII Associated with the Use of Interferon-alpha and Fludarabine , 2001, Thrombosis and Haemostasis.

[39]  H. Watson,et al.  Acquired haemophilia in association with organ‐specific autoimmune disease , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  J. Wan,et al.  Inhibitors against factor VIII in patients with cancer , 2001, Cancer.

[41]  M. Griesshammer,et al.  Acquired haemophilia: experiences with a standardized approach , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[42]  J. Voorberg,et al.  Disappearance of factor VIII autoantibodies preceding autoimmune haemolytic anaemia , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[43]  K. Pasi,et al.  A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. , 2000, Clinical and laboratory haematology.

[44]  G. Rivard,et al.  Suggestions for the management of factor VIII inhibitors , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[45]  N. Nguyen,et al.  Acquired hemophilia in patients with hematologic malignancies. , 2000, Archives of pathology & laboratory medicine.

[46]  J. Michiels,et al.  Acquired Hemophilia A in Women Postpartum: Clinical Manifestations, Diagnosis, and Treatment , 2000, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[47]  F. Blei,et al.  Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[48]  H. Liebman,et al.  Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII , 2000, American journal of hematology.

[49]  L. Rice,et al.  Surgery-associated factor VIII inhibitors in patients without hemophilia. , 1999, The American journal of the medical sciences.

[50]  K. Lechner,et al.  Solid Tumors and Factor VIII Antibodies , 1999, Thrombosis and Haemostasis.

[51]  I. Scharrer,et al.  Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[52]  Leissinger.  Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[53]  E. Santagostino,et al.  Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention , 1999, British journal of haematology.

[54]  G. Lippi,et al.  A combination of prednisone, high-dose intravenous immunoglobulin and desmopressin in the treatment of acquired hemophilia A with high-titer inhibitor. , 1999, Haematologica.

[55]  J. Pouchot,et al.  Acquired hemophilia due to factor VIII inhibitors in 34 patients. , 1998, The American journal of medicine.

[56]  G. Savidge,et al.  Acquired haemophilia A: errors in the diagnosis. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[57]  C. Hay.  1 Acquired haemophilia , 1998 .

[58]  C. Négrier,et al.  The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study , 1997, Thrombosis and Haemostasis.

[59]  C. Fabbri,et al.  Acquisition of factor VIII inhibitor after acute hepatitis C virus infection. , 1997, Blood.

[60]  H. Nieuwenhuis,et al.  Acquired haemophilia A in women postpartum: management of bleeding episodes and natural history of the factor VIII inhibitor , 1997, European journal of haematology.

[61]  C. Rothschild,et al.  Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors , 1997, Thrombosis and Haemostasis.

[62]  R. Chamuleau,et al.  Formation of Antibodies to Factor VIII in Patients with Hemophilia A Who Are Treated with Interferon for Chronic Hepatitis C , 1996, Annals of Internal Medicine.

[63]  R. Bech.  Recombinant factor VIIa in joint and muscle bleeding episodes. , 1996, Haemostasis.

[64]  C. Kessler,et al.  9 Acquired inhibitors , 1996 .

[65]  M. Surks,et al.  Graves' disease and autoimmune factor VIII deficiency. , 1996, Thyroid : official journal of the American Thyroid Association.

[66]  J. Lusher.  Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. , 1996, Haemostasis.

[67]  L. Bonomo,et al.  Development of factor VIII:C inhibitors following vaccination. , 1996, Acta haematologica.

[68]  R. Newman,et al.  Heparin contamination in coagulation testing and a protocol to avoid it and the risk of inappropriate FFP transfusion. , 1995, American Journal of Clinical Pathology.

[69]  M. Ries,et al.  Severe intracranial hemorrhage in a newborn infant with transplacental transfer of an acquired factor VII:C inhibitor. , 1995, The Journal of pediatrics.

[70]  C. Kessler,et al.  A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. , 1995, Blood.

[71]  K. Lechner,et al.  Post-Partum Factor VIII Inhibitors , 1995, Thrombosis and Haemostasis.

[72]  K. Sullivan,et al.  Spontaneous factor VIII inhibitor occurring in association with chronic graft‐versus‐host disease , 1994, American journal of hematology.

[73]  M. Robertson,et al.  Factor VIII inhibitor associated with hepatocellular carcinoma. , 2008, Clinical and Laboratory Haematology.

[74]  A. Rademaker,et al.  A Prospective, Randomized Trial of Prednisone and Cyclophosphamide in the Treatment of Patients with Factor VIII Autoantibodies , 1993, Thrombosis and Haemostasis.

[75]  W. Kane,et al.  DDAVP in acquired hemophilia a: Case report and review of the literature , 1993, American journal of hematology.

[76]  C. Kessler,et al.  Use of porcine factor VIII in the treatment of patients with acquired hemophilia. , 1993, Blood.

[77]  C. Kitchens,et al.  Acquired Hemophilia: A Natural History Study of 16 Patients With Factor VIII Inhibitors Receiving Little or No Therapy , 1987 .

[78]  C. Ludlam,et al.  Acquired Factor VIII Inhibitor Associated with Multiple Sclerosis, Successfully Treated with Porcine Factor VIII , 1987, Thrombosis and Haemostasis.

[79]  G. Mariani,et al.  Inhibitor to factor VIII in a non-haemophilic patient: evaluation of the response to DDAVP and the in vitro kinetics of factor VIII. A case report. , 1987, Nouvelle revue francaise d'hematologie.

[80]  L. Hoyer,et al.  Inactivation of factor VIII coagulant activity by two different types of human antibodies. , 1982, Blood.

[81]  M. Leyland,et al.  Acquired inhibitor to human factor VIII associated with paraproteinaemia and subsequent development of chronic lymphatic leukaemia. , 1982, British medical journal.

[82]  L. Hoyer,et al.  Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. , 1981, Blood.

[83]  K. Lechner,et al.  A Survey of 215 Non-Hemophilic Patients with Inhibitors to Factor VIII , 1981, Thrombosis and Haemostasis.

[84]  G. Brodeur,et al.  Acquired inhibitors of coagulation in nonhemophiliac children. , 1980, The Journal of pediatrics.

[85]  B. Wenz,et al.  Acquired factor VIII inhibitor in a patient with malignant lymphoma. , 1974, American Journal of the Medical Sciences.

[86]  J. Desforges,et al.  Spontaneous circulating anticoagulant (antifactor VIII). , 1962, The American journal of medicine.

[87]  D. Jackson,et al.  CIRCULATING ANTICOAGULANTS: A STUDY OF 40 CASES AND A REVIEW OF THE LITERATURE , 1961, Medicine.